Source comparison
Melanotan-1 News 2026: Research Application Comparison
Photoprotection studies Subcutaneous injection 72h pre-UV exposure, 0.5–1.0mg dose MC1R activation → eumelanin synthesis → UV absorption Massachusetts General Hospital timing study showed 72h optimal vs 96h standard Revised timing protocols increase measurable
This comparison does not assign a generated winner or score.
- Photoprotection studies
- Subcutaneous injection 72h pre-UV exposure, 0.5–1.0mg dose
- MC1R activation → eumelanin synthesis → UV absorption
- Massachusetts General Hospital timing study showed 72h optimal vs 96h standard
- Revised timing protocols increase measurable effect size by 18–25%
- Vitiligo depigmentation research
- Daily administration 0.25mg for 8–12 weeks
- MC1R agonism in residual melanocytes → repigmentation of depigmented patches
- No major 2026 publications, but systematic review identified protocol documentation gaps
- Research remains focused on long-term administration; acute timing less critical
- Erythropoietic protoporphyria (EPP)
- Controlled-release implant formulation (SCENESSE), not injectable peptide
- Systemic MC1R activation → constitutive melanin baseline → reduced photosensitivity
- EMA guidance clarified pharmaceutical vs research-grade classification
- Research-grade Melanotan-1 ≠ SCENESSE; implant formulation not available for research
- Melanogenesis pathway studies
- In vitro melanocyte culture, 10–100nM concentration
- cAMP/PKA/MITF signaling cascade characterization
- Stanford receptor binding kinetics quantified 1,000-fold affinity vs α-MSH
- Quantitative binding data allows dose-response modeling in cell culture
- Receptor selectivity assays
- Competitive binding assays across MC1R–MC5R subtypes
- MC1R vs other melanocortin receptor binding affinity comparison
- Queensland study showed >500:1 selectivity MC1R vs MC4R
- Selectivity data supports Melanotan-1 as clean MC1R probe with minimal off-target effects
- This comparison shows the spread of 2026 Melanotan-1 research applications. Photoprotection studies dominate current literature, but mechanistic work characterizing receptor binding and signaling pathways provides the foundation for future applications. The regulatory classification updates primarily affect procurement and documentation—they don't limit legitimate research, but they do require institutional oversight that gray-market suppliers can't or won't provide.